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Abstract
Magnetic resonance spectroscopy (MRS) is a non-invasive method, which can provide diagnostic
information on children with brain tumours. The technique has not been widely used in clinical
practice, partly because of the difficulty of developing robust classifiers from small patient numbers
and the challenge of providing decision support systems (DSSs) acceptable to clinicians. This paper
describes a participatory design approach in the development of an interactive clinical user interface,
as part of a distributed DSS for the diagnosis and prognosis of brain tumours. In particular, we
consider the clinical need and context of developing interactive elements for an interface that
facilitates the classification of childhood brain tumours, for diagnostic purposes, as part of the
HealthAgents European Union project. Previous MRS-based DSS tools have required little input
from the clinician user and a raw spectrum is essentially processed to provide a diagnosis sometimes
with an estimate of error. In childhood brain tumour diagnosis where there are small numbers of
cases and a large number of potential diagnoses, this approach becomes intractable. The involve-
ment of clinicians directly in the designing of the DSS for brain tumour diagnosis from MRS led to
an alternative approach with the creation of a flexible DSS that, allows the clinician to input prior
information to create the most relevant differential diagnosis for the DSS. This approach mirrors
that which is currently taken by clinicians and removes many sources of potential error. The validity
of this strategy was confirmed for a small cohort of children with cerebellar tumours by combining
two diagnostic types, pilocytic astrocytomas (11 cases) and ependymomas (four cases) into a class
of glial tumours which then had similar numbers to the other diagnostic type, medulloblastomas
(18 cases). Principal component analysis followed by linear discriminant analysis on magnetic
resonance spectral data gave a classification accuracy of 91% for a three-class classifier and 94% for
a two-class classifier using a leave-one-out analysis. This DSS provides a flexible method for the
clinician to use MRS for brain tumour diagnosis in children.
1 Introduction
Over the past decade, there have been substantial advances in the field of computer-aided decision
support for the early detection of cancer (Haque et al., 2002). At the same time, advanced bio-
logical characterization and innovative imaging modalities have provided novel approaches to
determining the diagnosis and prognosis of brain tumours (Howe & Opstad, 2003; Armstrong
et al., 2004). Early efforts in the implementation of interactive decision support systems (DSSs;
Underwood et al., 2001) for brain tumour diagnosis have identified the need to combine biomedical
automated pattern recognition techniques (Tate et al., 2006) and data from magnetic resonance
imaging (MRI) and advanced imaging techniques, such as spectroscopy (MRS), which provides
information on the biochemical profile of the tumour (Luts et al., 2007). Although it has shown
much promise, MRS has not been widely used in clinical practice partly because of the difficulty of
developing robust classifiers from small patient numbers and the challenge of providing DSSs
acceptable to clinicians. Most studies have concentrated on adult cases and there is an unmet need
for the application of such approaches to children and young adults, a group where brain tumours
are the most common solid tumours (Packer, 1999). However, the problems of small patient
numbers and a large number of diagnostic classes are particularly severe in this patient group.
The design and implementation of such an interactive DSS should reflect important elements
and steps of the decision-making process performed by a clinician. Such a process is usually
accomplished at different levels of abstraction and is supported by the clinical evidence available
to the clinician at the time. In the case of brain tumour diagnosis, the diagnostic process initially
involves the structured combination of clinical information, tumour biomarkers and imaging
modality indicators to formulate a list of potential diagnoses, often termed a differential diagnosis.
In this context, elements of this process should be correctly represented in the level of systems
requirements for the design and implementation of such DSSs. This is best achieved with the
support and involvement of actual users in the processes of requirements elicitation and design of
such a system. As such, Participatory Design (Schuler & Namioka, 1993) is an approach to
interactive systems design that seeks to actively involve end users in the various stages of the
design life-cycle of a system, ensuring that the final system meets users’ needs. Therefore, Parti-
cipatory Design is a very attractive way of successfully capturing the requirements of diagnostic
DSSs, as it encourages ownership of the development process by users (clinicians), while they are
addressing their own needs (Dredger et al., 2007).
A distributed DSS for the diagnosis and prognosis of brain tumours, termed HealthAgents, has
been previously described (Gonza´lez-Ve´lez et al., 2009). In this paper, we employ a participatory
design approach to develop an interactive clinical user interface for childhood brain tumours
within HealthAgents. In particular, we discuss the clinical need and context of developing inter-
active elements for an interface that facilitates the classification of childhood brain tumours, for
diagnostic purposes, as part of the HealthAgents European Union project. We provide the
argument for the clinical need for such a system and the constraints that should be imposed upon
the building of classifiers for childhood brain tumours. The constraints are based on tumour type,
patient age and tumour location. To illustrate the strategy and demonstrate its potential, classi-
fication results are presented from a small cohort of children with cerebellar tumours. The
HealthAgents project (The HealthAgents Consortium, 2009) has been developing a distributed
DSS, based on software agent technologies, in order to provide a set of automated classifiers for
the diagnosis and prognosis of brain tumours.
2 The need for decision support in the diagnosis of childhood brain tumours
Brain tumours are the most common solid tumours in children and young adults. They have a
poorer outcome than many other forms of cancer in this age group and the survivors often live
with a significant burden of neurological disability (Pizzo & Poplack, 2002). The diagnosis and
treatment of brain tumours has considerable ongoing challenges for clinical medicine. Magnetic
resonance imaging is the mainstay of non-invasive investigation for these patients, yielding
important information on location, size and heterogeneity of the tumour. However, MRI has a
limited ability to distinguish between different tumour types and provides little information on the
likelihood of treatment being successful (Barkovich et al., 2007). These limitations have led to
interest in developing alternative imaging methods, which can probe biological properties of tissue
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to give improved information on tumour type and prognosis. One method of particular interest is
magnetic resonance spectroscopy, which provides information on the biochemical composition of
selected volumes of tissue (Mukherji, 1998). There are many publications presenting non-invasive
diagnostic classifiers based on MRS for adults with brain tumours (Preul et al. 1996; Tate et al.,
2003), as well as MRS’s ability to predict and monitor response to treatment (Preul et al., 1998;
Nelson et al., 1999).
Childhood tumours are generally of different types to adult tumours, a fact which dictates that
specific diagnostic classifiers need to be built in the context of the disease in children. Even for
tumours which occur in all age groups, such as high grade gliomas, there is emerging evidence that
such tumours are considered to be different in children compared to adults (Barnett, 2007).
Therefore, data from tumour cases in adults should be used with extreme caution when developing
diagnostic classifiers for childhood tumours. Furthermore, though brain tumours are less common
in children than in adults, there exist a large number of different types of childhood brain tumours
(Pizzo & Poplack, 2002). The latter presents one of the considerable challenges for obtaining
sufficient cases to build robust classifiers for the disease in children.
The low incidence of each tumour type is compounded by an increasing subcategorization of
tumours (Louis et al., 2007), which is likely to be escalated with the discovery of new tumour
biomarkers. There is also increasing evidence that tumours of the same type have a different
biological profile when they arise in different locations of the brain (Pomeroy et al., 2000; Taylor
et al., 2005; Sharma et al., 2007). Given the large number of potential diagnostic categories, the
development of classifiers capable of giving a specific diagnosis from the complete list of tumour
types, based purely on MRS, is unlikely to be possible in the near future.
Although such development and implementation of classifiers to distinguish between all
childhood brain tumours is currently intractable, MRS classifiers can still play an important role
in clinical decision-making. The decision-making process undertaken by the clinicians involves the
increasing refinement of a list of potential diagnoses by the use of clinical information, tumour
markers in the blood and appearances on conventional Computerised Tomography and MRI.
Combining the multitude of information mentioned above, commonly allows the clinician to
narrow the diagnosis to a short list of two or three candidate diagnoses. Indeed, in a significant
proportion of cases there is deemed sufficient information to make a non-invasive diagnosis
without the need for new methods such as MRS (Pizzo & Poplack, 2002). An attractive approach
for clinicians, in support of the decision process, would be to select or build a classifier, which
specifically answers the particular clinical question posed.
Although narrowing the list of potential diagnoses can help the classification process by
reducing the number of diagnostic classes, the problem of small numbers in each class remains.
One approach to resolve this problem is to combine tumours, with related diagnoses, into the same
class. Brain tumours are currently diagnosed using the WHO 2007 classification (Louis et al.,
2007) and this is structured into specific diagnostic categories and subcategories. This allows
tumour groups to be combined together in a well-accepted manner, based on the similarity of their
histopathology. In addition to these groupings, clinicians often combine some of these groups
together for treatment purposes, since some tumours are known to behave similarly. A particular
example where tumours may be grouped to form a large class, is their grouping by tumour grade, a
marker of their aggressiveness. One can differentiate between low and high grade classes, since
most tumours in the WHO 2007 classification are typified by grade.
Building a DSS, which is sufficiently flexible to allow clinicians to select appropriate classifiers
or build a classifier from appropriate cases, has the potential to promote the clinical use of MRS in
paediatrics. Since diagnostic classification schemes are regularly updated by groups like WHO,
this information needs to be incorporated in a manner which allows straightforward revision and
maintenance. In addition, the system needs to have access to extensive MRS data sets and
associated, precise, tumour diagnoses in order to design, implement and train classifiers. There-
fore, high levels of adaptability and usability are also required for the DSS to be used efficiently in
a clinical environment.
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3 A participatory design approach in the development of a decision support system
for childhood brain tumours
There certainly exist many technical challenges in the development of clinical DSSs, mainly
relating to the complexity of the clinical decision process in the context of answering specific
clinical questions. However, over the past 20 years, we have experienced an increased and con-
tinuous proliferation of new examples of clinical DSSs for a large number of sub-specialities of
clinical medicine. Although existing clinical DSSs have proven their accuracy and reliability in
several cases (Shortliffe, 1987), many of such systems have failed to be adopted in routine clinical
use due to a variety of complex socio-technical issues (Barahona & Christensen, 1994; Hutton &
Prys-Roberts, 1994). In particular, the limited availability of appropriate data, the poor interface
design and the lack of appropriate considerations in the natural integration of such systems in the
context of clinical practice, are the major issues that have impeded the routine clinical use of DSSs.
In particular, clinicians are reluctant to adopt such systems, if their use does not fit naturally into
the process of healthcare provision (Barahona & Christensen, 1994).
To address the aforementioned socio-technical issues in the development of clinical DSSs
and accommodate the specific needs of the clinical decision support process and challenges that
exist in the development of optimal diagnostic classifiers for childhood tumours, based on MRS
and other associated clinical evidence, we have followed a participatory design approach in the
development of the paediatric-related decision support interactive functional elements for the
HealthAgents DSS.
The concept of participatory design has enabled us to involve clinicians as potential users of the
HealthAgents DSS to direct the processes of requirements analysis, design and interface imple-
mentation, while it has facilitated the initial clinical validation of the system within the context of
specific clinical questions. We conducted three requirements analysis workshops and 10 design
sessions, each of 1 hour, where clinical users provided input in designing the interface elements
corresponding to the paediatric childhood tumour decision support components of the HealthAgents
DSS. The identification of functional and non-functional requirements for these elements, together
with the design of workflow of the clinical decision process in the context of diagnosis of childhood
brain tumours from MRS and other associated clinical data, has originated directly from a group of
30 clinicians. This group consisted of clinical paediatric oncologists and neuroradiologists, all
members of the functional imaging group of the UK’s Children’s Cancer and Leukaemia Group
(CCLG). This group has an inclusive membership of both clinicians and scientists, with an overall
aim to encourage the development of new technologies and techniques to support the care of
children with cancer (CCLG, 2009).
We have chosen the participatory approach to encourage the clinical users’ ownership of
the developed elements of the HealthAgents DSS, rather than a simply user-driven methodology.
The later identifies the users as simply being the passive sources of initial system requirements
identification (Shneiderman, 2003), an approach that usually results in alienating the potential
users of the resulting system and as a consequence impedes the process of broader acceptance and
adoption of the system in the future (Magnusson et al., 2003, Sharp et al., 2007).
The web-based interface screens presented below represent the childhood tumour diagnosis part
of the interactive functional elements of the overall HealthAgents DSS, as derived through a
participatory design approach. The clinical user is able to initially upload the index case for which
he wishes to perform a diagnostic classification, by displaying MRS spectra in conjunction with
associated supporting elements of spectroscopy and imaging—position of voxel for single-voxel
MRS, magnetic resonance (MR) images associated with the case, etc.—under the ‘index case’
interface element of the system. Associated patient and clinical information for the index case, in
terms of gender, age of patient and anatomical location of the malignancy, are recorded under the
‘clinical information’ interface element of the system.
The clinician can then construct a set of diagnostic groups pertinent to the index case through
an interface screen labelled ‘differential diagnosis’ (Figure 1). Each diagnostic group is constructed
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by selecting one or more entries from the 2007 WHO classification list of tumours of the central
nervous system (brain and spine; Louis et al., 2007; Figure 1). The choices from the WHO 2007 list
constitute the query which will identify the existence of appropriate classifiers, in the HealthAgents
network of distributed nodes, for the clinician to use and run on their index case. The ability to
allow more than one WHO 2007 diagnosis to be combined in the same diagnostic group addresses
one of the important challenges that the CCLG group has identified: the low incidence of each
tumour type in children that is compounded by an increasing subcategorization of tumours.
Combining related diagnoses into the same group allows the identification of classifiers that
overcome the issue of low incidence of cases in each tumour type. In the following section, we
demonstrate this flexibility by considering the process of combining two specific tumour types,
Pilocytic Astrocytomas and Ependymomas into a single diagnostic group and comparing this
against another tumour type, Medulloblastomas, as a two-class classifier.
The design of the interface screens for both the ‘clinical information’ and ‘differential diagnosis’
interface elements of the system, has adopted the approach of dynamic tree-based presentation of
concepts that are encoded in the HaDOM (the HealthAgents Domain Ontology) which is dis-
cussed in detail by another paper within this special issue (Hu et al., in press). This ontology-based
approach has allowed the presentation of hierarchical trees of concepts that are presented as list of
choices in the interface, an interaction style that is particularly favoured by clinicians in the way
they prefer to identify information in computer-based information and DSSs (Boyes et al., 2007).
The ontology-based approach is particularly useful in this setting since diagnoses, which are
closely related, are located close to each other simplifying their co-selection.
The default query selects cases from all ages and tumour locations and both genders. However,
the system can refine this query for appropriate identification of classifiers by allowing the
clinician to re-determine information relating to age, gender and tumour location. To achieve this,
a user (clinician) can select specific age ranges, include one or both classes of gender and specify all
or specific locations for the malignancy, in an expandable/collapsible tree menu structure, made
available in the ‘refined differential diagnosis’ screen element. This interaction style assists the
clinician in refining his query and therefore identifying more appropriate candidate classifiers.
This refinement in the query for classifiers (Figure 2) addresses important challenges in the
diagnosis of childhood tumours, as identified in current evidence in the literature and by the
experience provided by the participating clinicians. For example, based on the input provided
from various clinicians in the participatory group, even for tumours which occur in all age groups,
Figure 1 Interface screen element for identifying potential differential diagnoses for the index case for which
classifiers are required
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such tumours may be considered to be different in children compared to adults, and therefore the
refinement of age ranges helps to identify the appropriate classifiers. This design decision provides
an approach which avoids using classifiers developed for adult cases being used inappropriately to
classify an index case of a childhood brain tumour. Equally, as elicited in the requirements capture
sessions, the choice of more specific anatomical locations can accommodate the identification
of specific classifiers that might exist in the HealthAgents DSS, which will differentiate some
histopathological types of tumour that have different biological profiles due to their growth in
specific anatomical locations in the brain.
Figure 3 shows the final part of the workflow, where the system will display any available
classifiers derived for the classification of the index case and allow the clinical user to run the
classifiers in order to support their clinical decision support process in establishing a diagnosis for
the index case. In this example, we display an instance, where two specific classifiers are provided
for discriminating between three different childhood tumour types, namely PNET (primitive
neuroectodermal tumour) a category which includes medulloblastoma, ependymoma and grade 1
astrocytoma, which is equivalent to pilocytic astrocytoma. This example will be further discussed
in the following section.
4 The healthagents childhood tumour clinical decision support interface:
an illustration of diagnosis for cerebellar tumours
In order to illustrate the functionality and flexibility of the childhood tumour DSS, we consider
the diagnosis of cerebellar tumours, a common clinical scenario in paediatric oncology. The
differential diagnosis is usually pilocytic astrocytoma, medulloblastoma and ependymoma.
Ependymomas are of low incidence, making it difficult to attain sufficient numbers of this tumour
type to build a robust classifier with this as a single class. The problems are compounded by
evidence that both ependymomas and pilocytic astrocytomas in the cerebellum differ from their
counterparts in different locations of the brain and the lack of these tumours in adults. This
section investigates the discrimination of the three tumour types medulloblastoma, ependymoma
Figure 2 Gender, age and location refinement of classification query
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and pilocytic astrocytoma using both a three-class classifier and a two-class classifier where the
pilocytic astrocytomas and ependymomas are combined into a single class of glial tumours. All
cases are taken from children with tumours in the cerebellum.
4.1 Training the classifiers
Data for training the classifiers was obtained from 33 children each with a suspected cerebellar
tumour. As each patient has a conventional MR image, this was used to delineate the margins of
the primary tumour and enabled the placement of the MRS voxel within the solid-appearing
component of the tumour. A single-voxel MRS (1.5 Tesla, PRESS, TE 30ms, TR 1500ms) was
performed. The diagnosis was obtained by surgical resection and histopathology yielding 11
pilocytic astrocytomas, four ependymomas and 18 medulloblastomas (the acquisition bandwidth
per point was 1.024Hz, cubic voxels with 2 cm or 1.5 cm length were used and 128 or 256
repetitions were acquired, respectively).
The MRS data were phased and 496 data points extracted using equal ppm spacings between
0.2 and 4.0 ppm. Each spectrum was then normalized by dividing each point by the sum of the
intensity values. A principal component analysis was performed for dimension reduction and
feature extraction. The principal components (PCs) were ordered according to the amount of
variance which they explained. The number of PCs used in the subsequent classification was then
chosen to be that which gave the optimal classification with an upper limit being the number which
explained 95% of the cumulative variance.
Each MRS was classified using LDA (linear discriminant analysis) of the PC scores. Optimized
feature selection was performed by minimizing the classification error in a leave-one-out (LOO)
analysis cross-validation loop, while increasing the number of PCs used.
4.2 Results of the MRS classification
The results of a three-class classifier are shown in Figure 4. A plot of the discriminant function
scores for each case based on eight PCs is shown in Figure 4(a). Discriminant function 1 separates
the pilocytic astrocytomas and the ependymomas from the medulloblastomas. Discriminant
Figure 3 Classifier identification and classification performance screen – an instance for differentiating three
different childhood tumour types, namely primitive neuroectodermal tumour (PNET), ependymoma and
grade 1 astrocytoma
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function 2 separates the ependyomomas from the pilocytic astrocytomas with the exception of one
ependymoma case that clusters more closely with the pilocytic astrocytomas. In Figure 4(b), it is
identified that the first 11 PCs of the spectra account for approximately 95% of the variance, with
almost 50% being accounted for by the first PC (Figure 4(b)). Optimum performance of the
classifier was reached using the first eight PCs. This resulted in a 91% (31/34) classification success
rate in a LOO analysis (with one case in each class being incorrectly classified). Figure 4(c) and (d)
shows plots of the corresponding spectral coefficients for the two discriminant functions. The
LOO external cross validation error was 21.2%.
A two-class classifier, in which the pilocytic astrocytomas and ependymomas were combined to
create a class of glial tumours, gave a classification success rate of 94% (32/34) using a LOO
analysis. One pilocytic astrocytoma and one medulloblastoma were incorrectly classified, all
ependymomas were classified correctly. The LOO external cross validation error was 14.7%.
4.3 Discussion
Although there are only a small number of cases in this study, the improved classification success
rate of the two-class classifier when compared with the three-class classifier supports the strategy
of combining diagnoses to create larger classes. The lower external cross validation error for
the two-class classifier further supports this approach. The finding that none of the incorrectly
classified cases, in the two-class classifier, were ependymomas demonstrates that this tumour
group can be successfully combined with pilocytic astrocytomas to form a larger class of glial
tumours. Where clinical and imaging findings restrict the likely diagnoses for the index case to
either a medulloblastoma or an ependymoma, a two-class classifier, such as that constructed in
this study, may be the most appropriate to use clinically.
Figure 4 Classification of cerebellar tumour type using pattern recognition of the normalised spectra
(method 1) showing (a) scatter plot of LDA of the first eight principal components (pilocytic astrocytoma
class represented by squares, ependymoma class represented by diamonds and medulloblastoma class
represented by circles), (b) distribution of variance being accounted for by the principle components, (c) and
(d) plot of the mean spectral coefficients for the discriminant functions 1 and 2 determined by the LOO
cross-validation procedure with 95% confidence intervals indicated by shaded area
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There are over 200 childhood cases with MRS in the HealthAgents data warehouse at present
with approximately equal numbers of brain tumours and other cases. This has allowed the con-
struction of a number of childhood-specific classifiers of clinical importance, including tumour
cases versus non-tumour, aggressive versus non-aggressive tumours and glial tumours versus
primitive neuroectodermal tumours. The classes in the latter two classifiers contain cases with a
variety of diagnoses demonstrating the approach advocated in this paper. There are some cases
where these classifiers will not answer the clinical question posed. For these scenarios, the clinician
can interrogate the database to find how many cases are available in the classes they wish to
define. Mean spectra or specific cases can then be used to aid diagnosis, where the number of
available cases is too few for a reliable classifier to be made available. As more cases are added to
the data warehouse, more specific classifiers will be developed allowing the clinician to select these
when appropriate.
5 Conclusion
We have presented a user participatory approach to the design, implementation and initial clinical
validation of a set of specialized interface elements to the HealthAgents DSS. The purpose of such
interactive functional elements is to support the clinical process of diagnosing childhood brain
tumours using MRS, by giving the user increased control over the selection of appropriate pattern
classification techniques. The participatory design approach has provided a modular and flexible
web-based interface that addresses some of the challenges of childhood tumour diagnostic process.
The design of interface screens has been supported by the systems’ domain ontology, allowing
clinicians to input clinical and differential diagnosis information in order to classify an index case
to specific diagnostic class. The participatory design approach has involved clinical users in
directing the design and implementation of the functional elements of the system. In addition, a
initial clinical validation of the usefulness of the current design was demonstrated by addressing
two important challenges in childhood tumour classification; the low incidence of certain tumour
types and appropriate restriction of cases by patient age and tumour location. To further benefit
from the participatory design approach, the interface and interactive functional elements could be
further evaluated by our clinical group from a viewpoint of usability and more additional user
acceptance studies in the clinical environment, to determine future deployment options of such a
DSS in clinical practice.
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